Apligraf® Has the Power To Transform the Wound Environment

**Description**
- Apligraf is designed with living, bioactive cells to LOOK, FUNCTION, and RESPOND like human skin.
- The epidermal layer contains LIVING KERATINOCYTES and STEM CELLS that provide potent healing signals (growth factors/cytokines).
- The dermal layer contains LIVING FIBROBLASTS that proliferate and produce human collagen and other extracellular matrix (ECM) proteins as well as growth factors and cytokines.

**Indications**
- Apligraf is the ONLY product FDA-approved to heal venous leg ulcers (VLUs) after 4 weeks of failed conventional therapy.
- Apligraf is also FDA-approved to heal diabetic foot ulcers (DFUs) after 3 weeks of failed conventional therapy.

**Cell Viability**
- Apligraf cells are BIOACTIVE and poised to heal.
- Apligraf is delivered ready to use with >90% CELL VIABILITY throughout its 15-day shelf life.

**Evidence of Mechanism of Action**
- Apligraf transmits potent healing signals (growth factors/cytokines) that CONVERT the wound from a CHRONIC to an ACUTE state.
- Keratinocytes activated at the wound edge
- Growth factor signaling regulated and corrected
- Inflammatory environment modulated
- ECM production balanced

**Empowering Healing**
- Healing VLUs
- Greater than 50% of the wounds were full-thickness
- Greater than 50% of the wounds were present for more than 1 year
- Wounds were large with a mean size of 14.2 cm

**For product information and technical, medical or reimbursement questions, please call 1-888-432-5232, OPTION 3.**
Empowering you to optimize VLU outcomes

Apligraf is delivered ready to use with ECM production balanced

Apligraf is the
Keratinocytes activated at the wound edge

The epidermal layer contains
Apligraf transmits potent healing signals (growth factors/cytokines)

The dermal layer contains
Apligraf is also FDA-approved to heal diabetic foot ulcers (DFUs) after 3 weeks of failed conventional therapy

Apligraf cells are
Healthy Skin
Apligraf is designed with living, bioactive cells to
To Transform the Wound Environment

Apligraf®
THE BIOTECH HEALER

*Stem cells are key contributors to Apligraf's signaling profile.
Carlson 6.

Evidence of Mechanism of Action

• Cell Viability
• Indications

Description

Incidence of VLU closure

Week 12

Week 24

Median time to VLU closure

Apligraf (n = 130)

Conventional care (n = 110)

Acute Wound Healed

3,4

100% HEALING

Conventional care had a 37% acute wound healing rate, while Apligraf had a 57% rate. Apligraf was significantly more efficacious than conventional care alone.

Medicare Coverage

• Apligraf is reimbur...s a skin substitute in the high bundle
• Apligraf is COVERED by 100% of local coverage determinations (LCDs)

Unsurpassed Commercial Insurance Coverage

• All commercial medical policies COVER Apligraf treatment
• Supplied in 44 sq cm
• Billed using HCPCS code Q4101 and CPT codes 15271-15278

For product information and technical, medical or reimbursement questions, please call 1-888-432-5232, OPTION 3.

Organogenesis, Inc. 2018
www.organogenesis.com

The information provided is for educational purposes only and shall not be construed as a statement, representation, or warranty of any kind. Data on file, Organogenesis Inc.

©2018 Organogenesis Inc. OI-A1273
All rights reserved. Printed in U.S.A. 8/18.

Apligraf is a registered trademark of Novartis.